Why the ResMed (ASX:RMD) share price slumped even as profit jumped

A 14% increase in quarterly revenue wasn’t enough to save the ResMed share price from profit takers.
The post Why the ResMed (ASX:RMD) share price slumped even as profit jumped appeared first on The Motley Fool Australia. –

The Resmed CDI (ASX: RMD) tumbled even as management unveiled a double-digit increase in quarterly revenue and a bigger dividend.

But that wasn’t enough to save the sleep-treatment device maker. The ResMed share price crashed by over 3% to $36.06 in early trade.

ResMed share price is worst performer

This makes it the worst performer on the S&P/ASX 200 Index (Index:^AXJO) at the time of writing.

That’s even worse than ASX gold miners, which dominated the rest of the bottom ranks due to the weak gold price.

The Perseus Mining Limited (ASX: PRU) share price, Ramelius Resources Limited (ASX: RMS) and Northern Star Resources Ltd (ASX: NST) are right behind ResMed.

Profit and dividend growth

ResMed posted a 14% uplift in fourth quarter revenue compared to the same time last year to US$876.1 million.

This means its FY21 full year revenue will be 8% ahead of the previous year at US$3.2 billion.

The medtech giant also upped its quarterly dividend by 8% to US42 cents a share. Not that this matters much as investors don’t buy the ResMed share price for its dividends.

Good news overshadowed by margin squeeze

But the news hasn’t gone down well with investors as ResMed’s margins are under pressure. Its non-GAAP gross margin fell 260 basis points (bps) to 57.3%. This dragged its full year margin down 70 bps to 59.1%.

ResMed said this is mainly due to an unfavourable product mix. Sales of lower-margin Sleep devices contributed more to group revenue this time round.

Further, lower average selling prices and foreign currency movements also weighed on margins. However, the foreign exchange “drag” bolstered ResMed’s top line. So, I can only surmise that currency movements didn’t have as big an impact on margins than the first two factors.

Profit takers hit the ResMed share price

Another reason why the ResMed share price came under pressure may have something to do with its 41% surge over the past year.

Shareholders sitting on strong returns would be looking for any excuse to lock in some profits. A margin squeeze is as good as any.

The fact that ResMed didn’t offer much in the way of an outlook also made the profit-taking decision that much easier.

Outlook failed to inspire

“Looking ahead, we are confident in our ability to grow steadily through our fiscal year 2022 and to deliver for all our stakeholders,” said ResMed’s chief executive, Mick Farrell.

“We’re driving accelerated adoption of digital health solutions in sleep apnea, COPD, and out-of-hospital care, accelerating our ResMed 2025 strategy.”

After a big run-up in the shares, investors will need more than assurances of steady growth to keep pushing ResMed higher – at least for now.

The post Why the ResMed (ASX:RMD) share price slumped even as profit jumped appeared first on The Motley Fool Australia.

Should you invest $1,000 in ResMed right now?

Before you consider ResMed, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and ResMed wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

More reading

ASX 200 midday update: REA & ResMed results, Afterpay jumps

How owning too much Afterpay (ASX:APT) was our biggest regret
ResMed (ASX:RMD) share price on watch after beating expectations in FY21
5 things to watch on the ASX 200 on Friday

These 2 hot ASX shares take up 20% of our fund: manager

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!